ArticleCureus2026
Ceftriaxone-Induced Immune Hemolytic Anemia and Subsequent Disseminated Intravascular Coagulation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced immune hemolytic anemia (DIIHA) is a rare but potentially life-threatening complication, most often associated with β-lactam antibiotics such as ceftriaxone. We report a 78-year-old woman who developed abrupt clinical deterioration and disseminated intravascular coagulation (DIC) within 30 minutes of ceftriaxone administration for pneumonia, resulting in death eight hours after exposure despite aggressive resuscitation. Laboratory studies confirmed ceftriaxone-dependent antibodies and a positive direct antiglobulin test (DAT), establishing the diagnosis of ceftriaxone-induced DIIHA with secondary DIC. This case underscores the fulminant and often fatal course of ceftriaxone-induced hemolytic anemia and highlights the critical importance of swift recognition and discontinuation of suspected offending agents in patients presenting with acute hemolysis and coagulopathy following antibiotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.